CSL Vifor

Showing 1 posts of 1 posts found.

europe-1395916_640

EU approval granted for rare kidney disease treatment

April 29, 2025
Market Access, Research and Development, Sales and Marketing CSL Vifor, EU, Nephrology, Travere Therapeutics, kidney disease, nephrology

The EU has granted marketing authorisation (MA) for Filspari – CSL Vifor and Travere Therapeutics’ therapy for primary IgA nephropathy …

The Gateway to Local Adoption Series

Latest content